Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

DUBLIN, May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ( " Theravance Biopharma " or the " Company " ) (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials